References
- Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483–2487.
- Deininger MW, O’Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637–1647.
- O’Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679–1689.
- Tibullo D, Giallongo C, La Cava P, et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009;37:461–468.
- El Hajj Dib I, Gallet M, Mentaverri R, et al. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006;551:27–33.
- Vandyke K, Fitter S, Dewar AL, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766–774.
- O’Sullivan S, Naot D, Callon K, et al. Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int 2011;88:16–22.
- Grey A, O’Sullivan S, Reid IR, et al. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006;355:2494–2495.
- O’Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009;94:1131–1136.
- Jönsson S, Standal T, Olsson B, et al. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 2012;87:550–552.
- Jönsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101–1103.
- Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006–2013.
- O’Sullivan S, Lin J-M, Watson M, et al. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011;49:281–289.
- Baldazzi V, Tassi R, Lapini A, et al. Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis. Cancer 2012;118:3165–3172.
- Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143–5150.
- Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–3412.
- McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.
- Reid IR. Relationships between fat and bone. Osteoporos Int 2008;19:595–606.
- Schmid H, Jaeger BAS, Lohse J, et al. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009;94:1177–1179.
- Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012;59:840–845.
- Mariani S, Giona F, Basciani S, et al. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111–112.
- Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011;159:676–681.
- Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012;59:481–484.
- Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?Biol Blood Marrow Transplant 2011;17:S115–S122.